SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC

SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC is a phase 3, randomised interventional study registered as NCT07549399 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 204 participants, started 2026-05-20 and due to reach its primary completion in 2029-04-30. Interventions recorded: Short-Course Radiotherapy; PD-1 monoclonal antibody; mFOLFOX6 regimen; Cetuximab; Bevacizumab; Surgical resection. Conditions listed: Rectal Adenocarcinoma; High-Risk Cancer; MSS. Primary outcome: 3 years DFS Rate. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed pMMR/MSS rectal adenocarcinoma; all other histological types are excluded". Sites: China. No results are recorded here; the registry entry is the source.